Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Jefferies Financial Group

Key Points

• Jefferies initiated coverage of Vertex with a Buy rating and a $580 price target — implying roughly 25.9% upside — while the street consensus is a "Moderate Buy" with an average target near $548.73.
• Vertex reported positive interim Phase 3 RAINIER results for povetacicept and is reportedly planning an FDA filing (by March), a development that has driven multiple analysts to raise price targets and represents a near-term catalyst.
• The company slightly missed quarterly EPS ($5.03 vs. $5.05 consensus) despite 9.5% YoY revenue growth, and insiders have been net sellers (91,156 shares worth about $42.8M last quarter), which could weigh on investor sentiment.

Stock analysts at Jefferies Financial Group initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) in a report released on Tuesday. The firm set a "buy" rating and a $580.00 price target on the pharmaceutical company's stock. Jefferies Financial Group's target price would indicate a potential upside of 25.85% from the company's current price.

A number of other research firms have also weighed in on VRTX. Wolfe Research raised Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 price objective for the company in a research report on Tuesday, January 6th. Wells Fargo & Company boosted their price target on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an "overweight" rating in a report on Wednesday, December 10th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, February 4th. HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $570.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Twenty-three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $548.73.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $460.87 on Tuesday. The stock has a market capitalization of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31. Vertex Pharmaceuticals has a 12 month low of $362.50 and a 12 month high of $519.68. The business has a 50 day simple moving average of $467.50 and a 200-day simple moving average of $435.79.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts' consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same period in the prior year, the firm earned $3.98 EPS. The business's quarterly revenue was up 9.5% on a year-over-year basis. On average, equities research analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 4,500 shares of the business's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00. Following the sale, the executive vice president directly owned 42,293 shares of the company's stock, valued at approximately $20,088,752.07. The trade was a 9.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Mark E. Bunnage sold 2,021 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the completion of the transaction, the executive vice president owned 12,914 shares of the company's stock, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 91,156 shares of company stock valued at $42,845,497. Company insiders own 0.20% of the company's stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Chesapeake Asset Management LLC lifted its position in Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 33 shares during the last quarter. Motiv8 Investments LLC bought a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $26,000. Colonial Trust Co SC raised its holdings in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 38 shares in the last quarter. Swiss RE Ltd. purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $28,000. Finally, Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $29,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Phase 3 RAINIER interim results met the primary and all secondary endpoints — Vertex reported strong Week 36 data showing povetacicept produced meaningful effects in adults with IgAN; the company described the readout as positive and the market reacted with after-hours buying. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: Company and press reports say the data are strong enough that Vertex plans an FDA filing (reportedly by March) for povetacicept, and headlines emphasized a late-session/share pop — a clear near-term catalyst for upside if regulators agree on the path. Vertex (VRTX) Stock Surges 5% Following Positive Kidney Disease Trial Results
• Positive Sentiment: Analysts reacted quickly: HC Wainwright raised its price target to $641 and kept a Buy rating; BMO Capital and William Blair reiterated Buy ratings with elevated targets (~$600 from BMO cited), reflecting expectations that povetacicept could be “best-in-class” in IgAN and add upside beyond Vertex’s cystic fibrosis cash flows. HC Wainwright price-target raise BMO / analyst coverage
• Neutral Sentiment: The RAINIER result cited is an interim analysis of an ongoing Phase 3 trial — strong interim data are encouraging but full trial readouts, regulatory review, and long-term safety/efficacy data remain to be confirmed. Investors should note the typical regulatory and commercialization execution risks. Yahoo Finance: Vertex interim analysis
• Negative Sentiment: Separately, Vertex’s most recent quarterly report showed a tiny EPS miss (reported 5.03 vs. 5.05 consensus) and, while revenue grew year-over-year, investors should weigh near-term valuation versus long-term pipeline upside. This older earnings miss could temper upside if pipeline approvals face delays. MarketBeat: VRTX profile / recent results

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.